Depakote Sprinkles (divalproex sodium) NDC 0074-6114

NDC codes

FDA NDC Directory

Product NDC (as listed)0074-6114Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00074-6114Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0074-6114-13	00074611413	100 CAPSULE in 1 BOTTLE (0074-6114-13)Marketed from Sep 12, 1989

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Depakote SprinklesSuffix: Sprinkles
Generic name (nonproprietary): divalproex sodium
Active ingredients: Divalproex sodium — 125 mg/1
Dosage form: Capsule
Route: Oral
Labeler: AbbVie Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 019680
Marketing start: Sep 12, 1989
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 0074-6114_d038b7e9-b014-4771-93be-90aeeaece03dSPL ID d038b7e9-b014-4771-93be-90aeeaece03dSPL set ID 4619aff4-0f80-444f-858d-42e4137aa809RxCUI 1099596, 1099598UNII 644VL95AO6UPC 0300746114130
Pharmacologic class: Anti-epileptic Agent; Mood Stabilizer

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400074611413 followed by a unit qualifier and the quantity

Package 00074-6114-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 31, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Depakote Sprinkle Capsules are an anti-epileptic drug indicated for: Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Depakote Sprinkle Capsules are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with complex partial seizures that occur either in isolation or in association with other types of seizures. Depakote Sprinkle Capsules are also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)